← Back to Search

Embolization Agent

the Terumo Hydropearl® microspheres device for Osteoarthritis (GAE Trial)

N/A

Waitlist Available

Led By Osmanuddin Ahmed, MD

Research Sponsored by University of Chicago

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Awards & highlights

GAE Trial Summary

This trial will test a new pain-relief procedure for people with osteoarthritis in their knees.

Eligible Conditions

Osteoarthritis of the Knee

GAE Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

KOOS Scale

Oswestry Disability Index

WOMAC Scale

Secondary outcome measures

KOOS for Knee Pain and Dysfunction

Opiate Usage

Oswestry Disability Index for Knee Pain and Dysfunction

+4 more

GAE Trial Design

1Treatment groups

Experimental Treatment

Group I: GAE ArmExperimental Treatment1 Intervention

Patients who meet study eligibility will be scheduled to undergo the Genicular Artery Embolization procedure and will subsequent be followed for 12 months after their procedure.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of ChicagoLead Sponsor

1,001 Previous Clinical Trials

817,725 Total Patients Enrolled

2 Trials studying Osteoarthritis

433 Patients Enrolled for Osteoarthritis

Osmanuddin Ahmed, MDPrincipal InvestigatorUniversity of Chicago

1 Previous Clinical Trials

100 Total Patients Enrolled

Media Library

Terumo Hydropearl® microspheres device (Embolization Agent) Clinical Trial Eligibility Overview. Trial Name: NCT04592562 — N/A

Osteoarthritis Research Study Groups: GAE Arm

Osteoarthritis Clinical Trial 2023: Terumo Hydropearl® microspheres device Highlights & Side Effects. Trial Name: NCT04592562 — N/A

Terumo Hydropearl® microspheres device (Embolization Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04592562 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research have any limitations on the age of participants?

"This trial is targeting individuals aged over 40 and beneath 80 years old."

Answered by AI

What are the main goals of this trial?

"The primary evaluation metric of this 12 month clinical trial is the KOOS Scale, with secondary objectives including reduction in knee pain and dysfunction (using the same score), a decrease in opiate usage, as well as patients' self-reported Visual Analog Score for Pain at 0, 3, 6 ,9 and 12 months."

Answered by AI

Who is eligible to partake in this clinical trial?

"To qualify for this medical research, a patient needs to have osteoarthritis in the knee and be between 40 and 80 years old. A total of 5 individuals are eligible to take part in the trial."

Answered by AI

Are there still open slots for participants in this experiment?

"Current information on clinicaltrials.gov shows that this particular medical trial is no longer recruiting individuals. Initially posted on September 22nd 2021 and with its most recent update occurring November 2nd 2022, the study has filled their quota of participants. Nevertheless, there remains 693 other trials actively looking for volunteers at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Genicular Artery Embolization to Reduce Pain Associated With Unilateral Mild to Moderate Osteoarthritis

2021. "Genicular Artery Embolization to Reduce Pain Associated With Unilateral Mild to Moderate Osteoarthritis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04592562.